ArticleAging and disease2022

Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton.

Roy B Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.